Ocular Therapeutix Inc
OCUL12.560USD
-0.150-1.18%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
2.20BMarket Cap
LossP/E TTM
More Details of Ocular Therapeutix Inc Company
Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company. AXPAXLI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases and conditions of the eye.
Ocular Therapeutix Inc Info
Ticker SymbolOCUL
Company nameOcular Therapeutix Inc
IPO dateJul 25, 2014
CEODugel (Pravin U)
Number of employees274
Security typeOrdinary Share
Fiscal year-endJul 25
Address15 Crosby Drive
CityBEDFORD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code01730
Phone17813574000
Websitehttps://www.ocutx.com/
Ticker SymbolOCUL
IPO dateJul 25, 2014
CEODugel (Pravin U)
Company Executives of Ocular Therapeutix Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Pravin U. Dugel, M.D.
Dr. Pravin U. Dugel, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
3.16M
-0.61%
Dr. Sanjay Nayak, M.B.B.S., Ph.D.
Dr. Sanjay Nayak, M.B.B.S., Ph.D.
Chief Strategy Officer
Chief Strategy Officer
277.86K
-0.67%
Dr. Richard L. Lindstrom, M.D.
Dr. Richard L. Lindstrom, M.D.
Independent Director
Independent Director
174.70K
+8.71%
Mr. Charles M. Warden
Mr. Charles M. Warden
Lead Independent Director
Lead Independent Director
74.46K
+23.15%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
50.00K
+38.89%
Ms. Merilee Raines, CPA
Ms. Merilee Raines, CPA
Independent Director
Independent Director
34.93K
+66.88%
Dr. Seung Suh Hong, Ph.D.
Dr. Seung Suh Hong, Ph.D.
Independent Director
Independent Director
34.93K
+66.88%
Mr. Donald D. Notman, Jr.
Mr. Donald D. Notman, Jr.
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Ms. Leslie J. Williams
Ms. Leslie J. Williams
Independent Director
Independent Director
--
--
Mr. Todd D.C. Anderman
Mr. Todd D.C. Anderman
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Pravin U. Dugel, M.D.
Dr. Pravin U. Dugel, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
3.16M
-0.61%
Dr. Sanjay Nayak, M.B.B.S., Ph.D.
Dr. Sanjay Nayak, M.B.B.S., Ph.D.
Chief Strategy Officer
Chief Strategy Officer
277.86K
-0.67%
Dr. Richard L. Lindstrom, M.D.
Dr. Richard L. Lindstrom, M.D.
Independent Director
Independent Director
174.70K
+8.71%
Mr. Charles M. Warden
Mr. Charles M. Warden
Lead Independent Director
Lead Independent Director
74.46K
+23.15%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
50.00K
+38.89%
Ms. Merilee Raines, CPA
Ms. Merilee Raines, CPA
Independent Director
Independent Director
34.93K
+66.88%
Revenue Breakdown
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
63.72M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.54%
VR Adviser, LLC
6.18%
Summer Road, LLC
5.70%
Deep Track Capital LP
5.60%
Avoro Capital Advisors LLC
4.81%
Other
63.18%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.54%
VR Adviser, LLC
6.18%
Summer Road, LLC
5.70%
Deep Track Capital LP
5.60%
Avoro Capital Advisors LLC
4.81%
Other
63.18%
Shareholder Types
Shareholders
Proportion
Investment Advisor
34.13%
Hedge Fund
22.63%
Investment Advisor/Hedge Fund
21.36%
Venture Capital
7.72%
Individual Investor
2.59%
Research Firm
2.32%
Private Equity
0.34%
Bank and Trust
0.28%
Pension Fund
0.20%
Other
8.44%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
364
156.52M
73.70%
+7.49M
2025Q2
382
145.09M
83.39%
-6.62M
2025Q1
391
145.03M
91.13%
-3.83M
2024Q4
382
137.38M
86.40%
-14.17M
2024Q3
370
142.63M
91.08%
-5.76M
2024Q2
356
140.04M
90.02%
+6.94M
2024Q1
335
125.94M
81.55%
+41.06M
2023Q4
313
75.41M
65.72%
+26.62M
2023Q3
319
44.73M
56.36%
-8.88M
2023Q2
327
47.63M
60.14%
-3.66M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
18.57M
8.81%
+17.66M
+1941.54%
Jun 30, 2025
VR Adviser, LLC
12.76M
6.05%
--
--
Jun 30, 2025
Summer Road, LLC
13.89M
6.59%
+9.45K
+0.07%
Jun 30, 2025
Deep Track Capital LP
14.29M
6.78%
--
--
Jun 30, 2025
Avoro Capital Advisors LLC
7.40M
3.51%
-660.00K
-8.19%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
9.34M
4.43%
-1.47M
-13.64%
Jun 30, 2025
The Vanguard Group, Inc.
8.37M
3.97%
+27.66K
+0.33%
Jun 30, 2025
TCG Crossover Management, LLC
5.32M
2.52%
--
--
Jun 30, 2025
Citadel Advisors LLC
4.89M
2.32%
+74.91K
+1.56%
Jun 30, 2025
Point72 Asset Management, L.P.
1.90M
0.9%
-38.15K
-1.96%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Invesco Pharmaceuticals ETF
2.53%
State Street SPDR S&P Pharmaceuticals ETF
2.33%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.66%
Invesco Dorsey Wright Healthcare Momentum ETF
0.8%
iShares U.S. Pharmaceuticals ETF
0.73%
Invesco Dorsey Wright SmallCap Momentum ETF
0.46%
First Trust Small Cap Growth AlphaDEX Fund
0.27%
Invesco Nasdaq Biotechnology ETF
0.2%
ProShares Ultra Nasdaq Biotechnology
0.2%
First Trust Small Cap Core Alphadex Fund
0.13%
View more
Invesco Pharmaceuticals ETF
Proportion2.53%
State Street SPDR S&P Pharmaceuticals ETF
Proportion2.33%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.66%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion0.8%
iShares U.S. Pharmaceuticals ETF
Proportion0.73%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.46%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.27%
Invesco Nasdaq Biotechnology ETF
Proportion0.2%
ProShares Ultra Nasdaq Biotechnology
Proportion0.2%
First Trust Small Cap Core Alphadex Fund
Proportion0.13%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Ocular Therapeutix Inc?
The top five shareholders of Ocular Therapeutix Inc are:
Fidelity Management & Research Company LLC holds 18.57M shares, accounting for 8.81% of the total shares.
VR Adviser, LLC holds 12.76M shares, accounting for 6.05% of the total shares.
Summer Road, LLC holds 13.89M shares, accounting for 6.59% of the total shares.
Deep Track Capital LP holds 14.29M shares, accounting for 6.78% of the total shares.
Avoro Capital Advisors LLC holds 7.40M shares, accounting for 3.51% of the total shares.
Fidelity Management & Research Company LLC holds 18.57M shares, accounting for 8.81% of the total shares.
VR Adviser, LLC holds 12.76M shares, accounting for 6.05% of the total shares.
Summer Road, LLC holds 13.89M shares, accounting for 6.59% of the total shares.
Deep Track Capital LP holds 14.29M shares, accounting for 6.78% of the total shares.
Avoro Capital Advisors LLC holds 7.40M shares, accounting for 3.51% of the total shares.
What are the top three shareholder types of Ocular Therapeutix Inc?
The top three shareholder types of Ocular Therapeutix Inc are:
Fidelity Management & Research Company LLC
VR Adviser, LLC
Summer Road, LLC
Fidelity Management & Research Company LLC
VR Adviser, LLC
Summer Road, LLC
How many institutions hold shares of Ocular Therapeutix Inc (OCUL)?
As of 2025Q3, 364 institutions hold shares of Ocular Therapeutix Inc, with a combined market value of approximately 156.52M, accounting for 73.70% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -9.69%.
What is the biggest source of revenue for Ocular Therapeutix Inc?
In FY2024, the -- business generated the highest revenue for Ocular Therapeutix Inc, amounting to -- and accounting for --% of total revenue.
